Novartis offloads a late-stage PI3Kẟ rare disease program in a discount deal
Looking to build on their franchise HAE drug Ruconest, Dutch biotech Pharming has snapped up a late-stage rare disease drug from Novartis for a modest upfront of only $20 million.
The pharma giant is selling global rights to CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor in development for Activated Phosphoinositide 3-kinase Delta Syndrome —or APDS. And Novartis will complete the Phase II/III registration study as well as an ongoing open-label expansion study for Pharming.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
